GlassScriptPhysician profile
Christos Ballas
NPI 1184618118
$3,476.93
in general payments reported to CMS, 2019-2025
26 companies · $362 in 2025
The $362 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,432 · 2020: $235 · 2021: $237 · 2022: $666 · 2023: $139 · 2024: $405 · 2025: $362.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $906.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,131.84 | 2019-2022 | |
| Astellas Pharma US INC | $403.58 | 2019-2025 | Veozah |
| Abbvie INC. | $282.87 | 2019-2025 | |
| Exeltis, USA INC. | $148.70 | 2021-2025 | Slynd |
| Mayne Pharma Commercial LLC | $131.14 | 2021-2023 | |
| Ethicon US, LLC | $125.60 | 2019-2024 | Enseal, Enseal X1 |
| Allergan, INC. | $119.55 | 2019 | |
| Myovant Sciences INC. | $103.99 | 2021-2022 | |
| Pfizer INC. | $103.34 | 2019-2021 | |
| Sage Therapeutics, LLC | $94.08 | 2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $92.31 | 2023-2025 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $76.71 | 2019-2023 | |
| Avion Pharmaceuticals | $75.85 | 2019-2022 | |
| Daiichi Sankyo INC. | $72.37 | 2020-2022 | |
| Amag Pharmaceuticals, INC. | $71.35 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $70.16 | 2019-2022 | |
| Millicent US INC | $67.30 | 2019-2025 | Intrarosa, Femring |
| Hologic Sales and Service, LLC | $65.68 | 2020-2022 | |
| Aspira Women'S Health INC | $48.50 | 2019-2022 | |
| Duchesnay USA Incorporated | $44.04 | 2019 | |
| Therapeuticsmd, INC. | $43.82 | 2019-2021 | |
| Amgen INC. | $30.42 | 2020 | |
| Merck Sharp & Dohme LLC | $27.02 | 2025 | Gardasil 9 |
| Agile Therapeutics, INC. | $19.24 | 2022 | |
| Organon LLC | $14.99 | 2022 | |
| Minerva Surgical, INC | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christos Ballas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.